Compare Emerson Electric Co. (EMR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Inovio Pharmaceuticals Inc — how do they compare? Emerson Electric Co. trades at $137.25 (market cap $76.31B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Emerson Electric Co. is far larger — about 792.7× Inovio Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EMR | INO | |
|---|---|---|
Market Cap | $76.31B | $96.26M |
Sector | Industrials | Health |
52-Week High | $161.69 | $2.87 |
52-Week Low | $123.30 | $1.05 |
Enterprise Value | $88.58B | $67.27M |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $136.11, showing modest daily gains amid a bearish technical signal. The company maintains solid fundamentals with a 13.35% net income margin and recent earnings beats, though valuation multiples like a P/E of 31.54 appear elevated. Analyst consensus is bullish with a $157.60 price target, but cash flow volatility and a high debt-to-asset ratio of 31.26% in 2025 pose concerns. Recent news highlights upcoming Q3 2026 earnings and growth in the Intelligent Devices segment.
EMR offers a balanced risk-reward profile; strong profitability and analyst support suggest upside, but technical weakness and financial leverage require caution. The stock's trajectory hinges on sustaining earnings momentum and managing debt, with key resistance near $137.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
